Johnson Lau, Athenex CEO (AP Images)
Struggling biotech sells its API manufacturing arm to narrow its focus
After a stock plunge in 2021 following a key FDA rejection, cancer biotech Athenex crashed into penny stock territory this year and is now looking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
